DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
RANCHO CORDOVA, Calif., Feb. 26, 2018 -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced the commercial launch of its AXP II system for the advanced isolation, collection and storage of hematopoietic stem cell concentrates from cord blood and peripheral blood.
“Since its introduction in 2006, our AXP system has been viewed as the gold standard in the volume reduction processing of cord blood, and we count many of the world’s leading public and private cord blood banks among our current long-time customers,” said Chris Xu, PhD, chief executive officer of Cesca Therapeutics. “Our first generation AXP system consistently achieves stem cell recovery rates in excess of 97%, the highest in the industry. With AXP II, we are introducing important enhancements to the AXP device, docking station, and proprietary XpressTRAK® software that together represent the biggest advancement in automated cord blood processing in many years. With the commercial launch of AXP II, we are continuing to fulfill our commitment to provide the highest quality, most innovative products to the cord blood bank market.”
AXP II is a complete, automated and functionally closed system that includes the AXP II device, docking station, processing set, and XpressTRAK software that maintains compliance with Current Good Manufacturing Practice (cGMP) and Current Good Tissue Practice (cGTP) regulations.
For more information, please visit: www.thermogenesis.com.
About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress platform that addresses the critical unmet need for better cellular manufacturing and controls (CMC) for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
[email protected]
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
[email protected]
